Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-04-22 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
审计报告2023-天健审〔2024〕2817号
Audit Report / Information Classification · 100% confidence The document is a detailed audit report for Hangzhou Anjiese Medical Technology Co., Ltd. It includes an audit opinion, basis for the opinion, key audit matters, management and governance responsibilities, and detailed financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes. The presence of an audit opinion section, detailed audit procedures, and extensive financial data confirms this is a standalone audit report. The document length is substantial (15,000 characters), and it contains actual financial data and audit analysis, not just an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR).
2024-04-22 Chinese
安杰思关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. It references previous announcements about the repurchase plan and reports on the ongoing execution of the buyback. The document is short (1460 characters) and focuses on the update of share repurchase activity rather than a full financial report or other types of filings. This matches the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2024-04-01 Chinese
安杰思关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase (buyback) activity. It details the number of shares repurchased, prices, total funds used, and references the company's share repurchase plan and regulatory compliance. It does not contain financial statements or earnings data, nor is it an annual or interim report. It is not a regulatory filing or announcement of a report publication. The content clearly fits the category of a Transaction in Own Shares (POS) filing, which covers share buyback activities.
2024-03-04 Chinese
安杰思2023年度业绩快报的公告
Earnings Release Classification · 95% confidence The document is titled as a "2023年度业绩快报的公告" which translates to "2023 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2023, including revenue, profit, and asset figures, but explicitly states that the data is preliminary and unaudited, with final audited data to be disclosed in the full 2023 Annual Report. The document is relatively short (2486 characters) and serves as a quick financial performance update rather than a comprehensive report. It also includes risk warnings about the preliminary nature of the data. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only, not the full audited report. Therefore, the document should be classified as an Earnings Release (ER). FY 2023
2024-02-26 Chinese
安杰思关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the company's first share repurchase through centralized bidding on the Shanghai Stock Exchange. It details the number of shares repurchased, prices, total funds used, and references the company's board approval and regulatory compliance. The document is short (1218 characters) and focuses on the share buyback transaction itself, not a financial report or earnings release. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company share repurchase announcements.
2024-02-22 Chinese
安杰思关于以集中竞价交易方式回购公司股份的回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from 杭州安杰思医学科技股份有限公司 regarding a share repurchase plan through centralized bidding. It includes specifics about the repurchase purpose, price limits, total funds allocated, duration, procedures, risks, and authorizations. The text discusses the company's intention to buy back shares for employee stock ownership or equity incentive plans, the board's approval, and regulatory compliance. It is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. The content is focused on the company's share repurchase activity, which fits the category of Transaction in Own Shares (POS). The document length (7,919 characters) and detailed content confirm it is the actual report of the repurchase plan, not just a brief announcement or certification.
2024-02-19 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.